Lonza to Expand Cytotoxic API Capacity in Switzerland
06:48 AM | May 12, 2011 | Deepti Ramesh
Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are...
This information is only available to subscribers.
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.